Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

REUTERS Other GLP-1 medications include Ozempic, Wegovy, Victoza, Saxenda, all made by Novo Nordisk. Fetterman noted that GLP ...

Novo Nordisk’s strong intangible assets in diabetes ... and biosimilar insulins have weighed on category pricing since 2017. Novo’s Victoza and Ozempic have made GLP-1 a key part of the ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Let's continue. Novo Nordisk's semaglutide franchise consists of Ozempic, Rybelsus, and Victoza, whose sales totaled about DKK 40.77 billion in the last three months of 2024, up 15.6% quarter-on ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...